X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs IPCA LABS - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA IPCA LABS FULFORD INDIA/
IPCA LABS
 
P/E (TTM) x 398.8 28.6 1,395.0% View Chart
P/BV x 6.2 3.6 170.9% View Chart
Dividend Yield % 0.1 0.1 65.6%  

Financials

 FULFORD INDIA   IPCA LABS
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
IPCA LABS
Mar-18
FULFORD INDIA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs942695 135.5%   
Low Rs450400 112.5%   
Sales per share (Unadj.) Rs691.4260.2 265.7%  
Earnings per share (Unadj.) Rs11.519.0 60.4%  
Cash flow per share (Unadj.) Rs15.433.1 46.5%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.30.2 157.4%  
Book value per share (Unadj.) Rs380.0213.0 178.4%  
Shares outstanding (eoy) m3.90126.20 3.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.02.1 47.8%   
Avg P/E ratio x60.728.9 210.3%  
P/CF ratio (eoy) x45.316.6 273.5%  
Price / Book Value ratio x1.82.6 71.2%  
Dividend payout %17.45.3 331.0%   
Avg Mkt Cap Rs m2,71469,120 3.9%   
No. of employees `0000.413.3 3.3%   
Total wages/salary Rs m5057,359 6.9%   
Avg. sales/employee Rs Th6,073.02,477.4 245.1%   
Avg. wages/employee Rs Th1,137.4555.2 204.9%   
Avg. net profit/employee Rs Th100.7180.6 55.7%   
INCOME DATA
Net Sales Rs m2,69632,836 8.2%  
Other income Rs m125418 30.0%   
Total revenues Rs m2,82233,254 8.5%   
Gross profit Rs m-464,505 -1.0%  
Depreciation Rs m151,777 0.9%   
Interest Rs m10240 4.0%   
Profit before tax Rs m542,905 1.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m10511 1.9%   
Profit after tax Rs m452,394 1.9%  
Gross profit margin %-1.713.7 -12.5%  
Effective tax rate %17.717.6 100.5%   
Net profit margin %1.77.3 22.7%  
BALANCE SHEET DATA
Current assets Rs m1,73819,455 8.9%   
Current liabilities Rs m54510,076 5.4%   
Net working cap to sales %44.328.6 155.0%  
Current ratio x3.21.9 165.3%  
Inventory Days Days4898 49.5%  
Debtors Days Days467 6.4%  
Net fixed assets Rs m1220,260 0.1%   
Share capital Rs m39252 15.5%   
"Free" reserves Rs m1,44326,633 5.4%   
Net worth Rs m1,48226,886 5.5%   
Long term debt Rs m02,340 0.0%   
Total assets Rs m2,07741,173 5.0%  
Interest coverage x6.713.1 51.3%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.30.8 162.8%   
Return on assets %2.66.4 40.8%  
Return on equity %3.08.9 33.9%  
Return on capital %4.310.8 40.0%  
Exports to sales %047.6 0.0%   
Imports to sales %24.514.9 164.4%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs m6594,884 13.5%   
Fx inflow Rs m1715,642 0.1%   
Fx outflow Rs m6734,884 13.8%   
Net fx Rs m-65610,759 -6.1%   
CASH FLOW
From Operations Rs m903,411 2.6%  
From Investments Rs m105-1,354 -7.7%  
From Financial Activity Rs m-14-1,304 1.1%  
Net Cashflow Rs m181753 24.0%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 11.4 33.3%  
FIIs % 0.1 25.3 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 17.4 121.8%  
Shareholders   4,783 36,892 13.0%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  NOVARTIS  TTK HEALTHCARE  MERCK LTD  

Compare FULFORD INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 134 Points Lower; Metal and Telecom Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended marginally lower. Sectoral indices ended on a mixed note with stocks.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

This Trend Will Produce a Once in a Lifetime Opportunity to Buy Stocks(The 5 Minute Wrapup)

Jan 15, 2019

Unlike his habit of pouring out stock wisdom in his annual letters to shareholders, Buffett spoke of this trend only once every few decades.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

My Next Small Cap Recommendation Is Practically a 'No Brainer'(Profit Hunter)

Jan 14, 2019

With a strong debt free balance sheet in its favour, attractive dividends and trading at almost lifetime lows, this investing idea is almost a no brainer.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 8-QTR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS